It took nearly 20 years for Protein Degrader technology to transform from academia to preclinical and clinical drug development projects. In 2019, Protein Degrader obtained the clinical proof of concept in oncologyRead More…
There are about 514 different protein kinases operating in human cells, accounting for 2.5% of the entire human genome. For scientists who want to use targeted protein degradation (TPD) technology to destroyRead More…
The wide range of application and the great potential in overcoming drug resistance and targeting non-proprietary targets, research and development in Protein Degrader field has been hot in recent years. Protein Degrader,Read More…
Protein Degraders, also named as Proteolysis-Targeting Chimeras, is a new type of drug that is different from antibodies and traditional small molecular inhibitors. It consists of target proteins ligand, linker, and E3Read More…
Protein Degrader, proteolysis targeting chimera, or proteolytic targeted chimera, is a new type of drug different from antibodies and traditional small molecule inhibitors. Protein Degrader consists of target protein binder, linker, andRead More…
Recently, Pfizer and Arvinas announced a partnership to develop and commercialize ARV-471, an oral Protein Degrader estrogen receptor protein degrader under development. Estrogen receptor (ER) is a well-known disease driver in mostRead More…
Main steps of Protein Degrader to achieve intracellular protein degradation To achieve intracellular protein degradation requires multiple steps, such as cellular uptake, effective recruitment of E3 ligase, ubiquitination of target proteins, andRead More…
In 2004, the Nobel Prize in Chemistry was awarded to Israeli scientists Aaron Sichanova, Afram Hershko and American scientist Irwin Ross for their discovery of ubiquitin-regulated protein degradation. Protein degradation is ratedRead More…
Recently, Pfizer and Arvinas jointly announced that they have reached an agreement to co-develop and promote the Protein Degrader protein degrader ARV-471. Arvinas will receive $650 million in upfront payments and potentiallyRead More…
Over the past decade, major changes have taken place in the field of drug targets. Although the traditional target is still the main direction, the R&D trend is gradually shifting from traditionalRead More…